GoodRx (NASDAQ:GDRX) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of GoodRx (NASDAQ:GDRX) from a buy rating to a hold rating in a research report released on Sunday.

Several other brokerages have also recently commented on GDRX. UBS Group reissued a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. JPMorgan Chase & Co. reduced their price target on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Morgan Stanley decreased their price target on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. Finally, Barclays began coverage on GoodRx in a research note on Monday, December 8th. They set an “underweight” rating and a $3.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.73.

GoodRx Trading Down 0.4%

NASDAQ:GDRX opened at $2.56 on Friday. The company has a market cap of $868.94 million, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 0.97 and a beta of 1.45. GoodRx has a twelve month low of $2.47 and a twelve month high of $5.81. The business has a 50 day moving average price of $2.75 and a two-hundred day moving average price of $3.65. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same quarter last year, the business earned $0.08 earnings per share. GoodRx’s revenue for the quarter was up .4% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GDRX. Quarry LP acquired a new position in shares of GoodRx during the 3rd quarter worth approximately $33,000. Boothbay Fund Management LLC bought a new position in GoodRx during the third quarter worth $43,000. Shay Capital LLC bought a new position in GoodRx during the third quarter worth $47,000. Cetera Investment Advisers acquired a new position in shares of GoodRx in the second quarter valued at $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in shares of GoodRx in the second quarter valued at about $55,000. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.